FungiScope™—Global Emerging Fungal Infection Registry

Mycoses

Volumn 60, Issue 8, 2017, Pages 508-516

  Seidel, Danila ^a   Durán Graeff, Luisa A ^a   Vehreschild, Maria J G T ^a,b,c   Wisplinghoff, Hilmar ^b,d,e   Ziegler, Maren ^d   Vehreschild, J Janne ^a,b,c   Liss, Blasius ^f   Hamprecht, Axel ^b   Köhler, Philipp ^a,b   Racil, Zdenek ^g   Klimko, Nikolay ^h   Sheppard, Donald C ⁱ   Herbrecht, Raoul ^j   Chowdhary, Anuradha ^k   Cornely, Oliver A ^a,b   FungiScope, G ^l  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c German Centre for Infection Research (DZIF)   (Germany)

^d Wisplinghoff Medical Laboratories   (Germany)

^e UNIVERSITY OF WITTEN HERDECKE   (Germany)

^f Neurologic Clinic   (Germany)

^g UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^h NORTH WESTERN STATE MEDICAL UNIVERSITY NAMED AFTER I I MECHNIKOV   (Russian Federation)

ⁱ RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^j UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^k UNIVERSITY OF DELHI   (India)

^l University Hospital of Cologne ^*

more..

Author keywords

fungal infection; global cooperation; immunocompromised; orphan disease; registry

Indexed keywords

AMPHOTERICIN B; ISAVUCONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ANTIFUNGAL THERAPY; ARTICLE; ASPERGILLUS; ATTITUDE TO HEALTH; BLASTOMYCOSIS; CANDIDA; COCCIDIOIDOMYCOSIS; CRYPTOCOCCUS NEOFORMANS; EUMYCETOMA; FUNDING; HISTOPLASMOSIS; HUMAN; MAJOR CLINICAL STUDY; MUCORMYCOSIS; MULTICENTER STUDY; NONHUMAN; PATIENT CARE; PNEUMOCYSTIS JIROVECI; PRIORITY JOURNAL; QUALITY CONTROL; RARE DISEASE; REFERENCE DATABASE; REGISTER; RETROSPECTIVE STUDY; SYSTEMIC MYCOSIS; COMMUNICABLE DISEASE; GLOBAL HEALTH; IMMUNOCOMPROMISED PATIENT; MYCOSIS; STANDARDS;

COMMUNICABLE DISEASES, EMERGING; GLOBAL HEALTH; HUMANS; IMMUNOCOMPROMISED HOST; INVASIVE FUNGAL INFECTIONS; MYCOSES; QUALITY CONTROL; RARE DISEASES; REGISTRIES;

EID: 85024908436     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12631     Document Type: Article

References (39)

1. Slavin M, van Hal S, Sorrell TC, et al. Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality. Clin Microbiol Infect. 2015;21:e1-e10.
2. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50:1091-1100.
3. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50:1101-1111.
4. Taccone FS, Van den Abeele AM, Bulpa P, et al. Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes. Crit Care. 2015;19:7.
5. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91:1068-1075.
6. Singh A, Singh PK, Kumar A, et al. Molecular and matrix-assisted laser desorption ionization-time of flight mass spectrometry characterization of clinically significant melanized fungi in India. J Clin Microbiol. 2017;55:1090-1103.
7. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54(Suppl 1):S23-S34.
8. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47:503-509.
9. Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014;20(Suppl 3):5-26.
10. Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102:433-444.
11. Tortorano AM, Richardson M, Roilides E, et al. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect. 2014;20(Suppl 3):27-46.
12. Chowdhary A, Meis JF, Guarro J, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. Clin Microbiol Infect. 2014;20(Suppl 3):47-75.
13. Arendrup MC, Boekhout T, Akova M, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. Clin Microbiol Infect. 2014;20(Suppl 3):76-98.
14. Cornely OA, Cuenca-Estrella M, Meis JF, Ullmann AJ. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) and European Confederation of Medical Mycology (ECMM) 2013 joint guidelines on diagnosis and management of rare and emerging fungal diseases. Clin Microbiol Infect. 2014;20(Suppl 3):1-4.
15. Tacke D, Koehler P, Markiefka B, Cornely OA. Our 2014 approach to mucormycosis. Mycoses. 2014;57:519-524.
16. ClinicalTrials.gov Identifier: Fungiscope NCT01731353. https://clinicaltrials.gov/ct2/show/NCT01731353?term=NCT01731353&rank=1 Accessed February 18, 2016.
17. Questback GmbH. Surveys & feedback solutions. http://www.questback.com Accessed February 28, 2017.
18. FDA. Approval letter for Cresemba (isavuconazonium sulfate). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000Approv.pdf Accessed January 21, 2016.
19. Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16:828-837.
20. European Medicines Agency. Summary of the European Public Assessment Report (EPAR) for Cresemba (isavuconazole). http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002734/human_med_001907.jsp&mid=WC0b01ac058001d124 Accessed September 1, 2016.
21. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813-1821.
22. Rickerts V, Khot PD, Myerson D, Ko DL, Lambrecht E, Fredricks DN. Comparison of quantitative real time PCR with Sequencing and ribosomal RNA-FISH for the identification of fungi in formalin fixed, paraffin-embedded tissue specimens. BMC Infect Dis. 2011;11:202.
23. Millon L, Herbrecht R, Grenouillet F, et al. Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF). Clin Microbiol Infect. 2016;22:e1-e8.
24. Ullmann AJ, Cornely OA, Donnelly JP, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. Clin Microbiol Infect. 2012;18(Suppl 7):1-8.
25. Nucci M, Marr KA, Vehreschild MJ, et al. Improvement in the outcome of invasive fusariosis in the last decade. Clin Microbiol Infect. 2014;20:580-585.
26. Pana ZD, Seidel D, Skiada A, et al. Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries. BMC Infect Dis. 2016;16:667.
27. Pagano L, Cornely OA, Busca A, et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica. 2013;98:e127-e130.
28. Recommendations for the conduct, reporting, editing and publication of scholarly work in medical journals. http://icmje.org/recommendations/browse/ Accessed Feburary 28, 2017.
29. Kalager M, Adami HO, Bretthauer M. Recognizing Data Generation. N Engl J Med. 2016;374:1898.
30. Hirsch JE. An index to quantify an individual's scientific research output. Proc Natl Acad Sci USA. 2005;102:16569-16572.
31. Web of science. https://webofknowledge.com/ Accessed May 31, 2016.
32. Jung J, Park YS, Sung H, et al. Assessment of the accuracy of histomorphologic diagnosis of aspergillosis and mucormycosis by immunohistochemical tests. Clin Infect Dis. 2015;61:1664-1670.
33. Lehrnbecher T, Frank C, Engels K, Kriener S, Groll AH, Schwabe D. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect. 2010;61:259-265.
34. Ruping MJ, Heinz WJ, Kindo AJ, et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother. 2010;65:296-302.
35. de Hoog GS, Robert V, Lackner M, et al. Making moulds meet. Information retrieval as a basis for understanding Pseudallescheria and Scedosporium. Mycoses. 2011;54(Suppl 3):1-4.
36. Christopeit M, Lindner A, Surov A, et al. Right flank pain and high fever in a neutropenic patient with acute lymphoblastic leukaemia. Mycoses. 2013;56:90-92.
37. Fischer J, Hamacher L, Fries J, et al. Rhodotorula mucilaginosa as a cause of recurrent pulmonary infection and liver infiltration in a patient with CLL. Ann Hematol. 2016;95:1569-1570.
38. Hassler A, Lieb A, Seidel D, et al. Disseminated fusariosis in immunocompromised children-analysis of recent cases identified in the Global Fungiscope Registry. Pediatr Infect Dis J. 2017;36:230-231.
39. Duran Graeff L, Seidel D, Vehreschild MJ, et al. Invasive infections due to Saprochaete and Geotrichum species: report of 23 cases from the FungiScope Registry. Mycoses. 2017;60:273-279.